Prospective single arm open clinical trial to study the efficacy of chaturbhadra leha in management of kaphaja kasa with special reference to URTI
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 试验地点
- 1
研究概览
简要总结
This is single arm open clinical trial
This study is being conducted to evaluate efficacy of chaturbhadra leha in management of kaphaj kasa with special reference to URTI
After screening patients at opd and ipd level 50 patients will be selected for trial informed written consent will be taken in native language
kaphaja kasa often best compared with urti due to similarities of signs and symptoms The prevalence rate of urti varies in india but in study 2022 found that among adults aged 14 to 59 the incidence was 21%
Null Hypothesis
chaturbhadra leha 2 gm orally twice a day for 14 days is not significantly effective in kaphaja kasa with special reference to urti
Alternative Hypothesis
chaturbhadra leha 2 gm orally twice a day for 14 days is significantly effective in kaphaja kasa with special reference to urti
Drug - chaturbhadra leha
Dose—2 gm twice a day
Anupana - Koshna Jala
Sevan kala- Vyanodan
Duration - 14 days
Follow up - 7th and 14th days
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •patients presenting with symptoms of kaphaja kasa with kasa veg kapha nishthivan kanthshool angamrda jwara patients age between 18 to 70 yrs of either sexes.
排除标准
- •patients with known case of TB lung cancer interstitial lung disease pneumonia pneumothorax copd patients with severe illness like HIV malignancy uncontrolled DM arrhythmia autoimmune disorder pregnant women and lactating mothers.
研究者
Dr Bhakti Pramod Meru
Sheth Chandanmal Mutha Aryangla Vaidyak Mahavidyalaya,Satara